ALK
HGNC:427 · 29 retained evidence mentions
Source-grounded findings
Supporting evidence
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | ALK | “Data regarding IMTs in adulthood is limited, and evidence suggests that ALK expression/rearrangement rate decreases with age.” | 0.98 | hgnc_dict_v1 |
| gene | ALK | “While oncogenic drivers, such as MYCN amplification and ALK mutations have been extensively investigated, accumulating genomic and epigenomic evidence indicates that disruption of tumor suppressor gene (TSG) networks plays a central role in neuroblastoma pathogenesis.” | 0.98 | hgnc_dict_v1 |
| gene | ALK | “This study aims to investigate the prevalence of ALK, EGFR, KRAS, ROS1, MET, BRAF, and HER2 mutations in patients with NSCLC within the Middle East and North Africa (MENA) region and to assess the current state of molecular testing and targeted treatments in the Gulf Cooperation Council (GCC) region.” | 0.98 | hgnc_dict_v1 |
| gene | ALK | “Exploring the mutational spectrum of key kinase genes PIK3CA, BRAF, EGFR, ALK and ROS1 in oral squamous cell carcinoma.” | 0.98 | hgnc_dict_v1 |
| gene | ALK | “RNA sequencing technology based on TEP demonstrates excellent diagnostic power by correctly identifying LC patients alongside their oncogenic alterations of EGFR, KRAS, and ALK.” | 0.98 | hgnc_dict_v1 |
| gene | ALK | “Other mutations detected include Anaplastic Lymphoma Kinase (ALK) and phosphatidylinositol 3-kinase (PIK3C) mutations in two patients.” | 0.98 | hgnc_dict_v1 |
| gene | ALK | “Brigatinib (BGT), a powerful small-molecule tyrosine kinase inhibitor, has demonstrated significant therapeutic potential in the treatment of NSCLC with anaplastic lymphoma kinase (ALK) mutations.” | 0.98 | hgnc_dict_v1 |
| gene | ALK | “Anaplastic lymphoma kinase rearrangement-associated renal cell carcinoma (ALK-RCC) is a rare subtype of renal cell carcinoma characterized by genetic rearrangements involving the ALK gene.” | 0.98 | hgnc_dict_v1 |
| gene | ALK | “Small molecule inhibitors targeting genetic mutations like EGFR and ALK have shown promise in NSCLC treatment.” | 0.98 | hgnc_dict_v1 |
| gene | ALK | “Zotizalkib (ZTK, TPX-0131) is a fourth-generation highly effective inhibitor of wild-type anaplastic lymphoma kinase (ALK) and ALK-resistant mutations that can penetrate the central nervous system.” | 0.98 | hgnc_dict_v1 |
| gene | ALK | “Among our findings, we have identified that ALK, VHL, CTNNB1, EGFR, ERBB4, PDGFRA, KDR, SMO, ABL1, HRAS, ATM, HNF1A, FLT3, and RB1 mutations are common for psammomatous meningioma and angiomatous tumours.” | 0.98 | hgnc_dict_v1 |
| gene | ALK | “Epidermal growth factor receptor (EGFR) mutations were positive in two (4.5%) cases and ALK mutation was positive in two (4.5%) cases.” | 0.98 | hgnc_dict_v1 |
| gene | ALK | “The Use of Crizotinib in Sclerosing Epithelioid Fibrosarcoma with ALK Mutation: A Case Report.” | 0.98 | hgnc_dict_v1 |
| gene | ALK | “Alectinib, also known as Alecensa®, is prescribed for the therapeutic treatment of individuals diagnosed with metastatic non-small cell lung cancer (NSCLC) who have a specific genetic mutation referred to as anaplastic lymphoma kinase (ALK) positivity.” | 0.98 | hgnc_dict_v1 |
| gene | ALK | “CER has been approved for the treatment of patients with non-small-cell lung cancer (NSCLC) harboring the anaplastic lymphoma kinase (ALK) mutation gene.” | 0.98 | hgnc_dict_v1 |
| gene | ALK | “Molecular abnormalities related to epidermal growth factor receptor (EGFR), v-Raf murine sarcoma viral oncogene homolog B1 (B-RAF) Kirsten rat sarcoma virus (KRAS) mutations, translocation of the anaplastic lymphoma kinase (ALK) gene, mesenchymal-epithelial transition factor (MET) amplification have been studied to overcome the resistance and to develop new therapies for non-small cell lung cancer (NSCLC).” | 0.98 | hgnc_dict_v1 |
| gene | ALK | “For the anaplastic lymphoma kinase (ALK) gene, 13% were found to be mutated; for the ROS proto-oncogene 1 (ROS1) gene, only 7% were seen to be mutated.” | 0.98 | hgnc_dict_v1 |
| gene | ALK | “Multiple robust and well-tolerated TKIs targeting single or multiple targets, including EGFR, ALK, ROS1, HER2, NTRK, VEGFR, RET, MET, MEK, FGFR, PDGFR, and KIT, have been developed over the last two decades, contributing to our understanding of precision cancer medicine based on a patient's genetic alteration profile.” | 0.98 | hgnc_dict_v1 |
| gene | ALK | “Analysis of ALK, IDH1, IDH2 and MMP8 somatic mutations in differentiated thyroid cancers.” | 0.98 | hgnc_dict_v1 |
| gene | ALK | “To understand disease pathology and to uncover novel targets for therapy, Whole-Exome Sequencing (WES) of Anaplastic Lymphoma Kinase (ALK)+ ALCL was performed as well as Gene-Set Enrichment Analysis.” | 0.98 | hgnc_dict_v1 |
| gene | ALK | “833 samples of non-small cell lung cancer from 799 patients who received resection of their lung cancer, were selected for molecular analysis of six known mutations, including EGFR, KRAS, BRAF, PIK3CA, HER2 and ALK.” | 0.98 | hgnc_dict_v1 |
| gene | ALK | “A Computer - Aided Drug Designing for Pharmacological Inhibition of Mutant ALK for the Treatment of Non-small Cell Lung Cancer.” | 0.98 | hgnc_dict_v1 |
| gene | ALK | “Alkaptonuria (ALK) is a rare genetic disorder, characterized by binding of ochronotic pigment to the connective tissues in different tissues.” | 0.98 | hgnc_dict_v1 |
| gene | ALK | “The absence of a novel intron 19-retaining ALK transcript (ALK-I19) and MYCN amplification correlates with an excellent clinical outcome in neuroblastoma patients.” | 0.98 | hgnc_dict_v1 |
| gene | ALK | “About 50% of cases harbor an anaplastic lymphoma kinase (ALK) gene rearrangement, and recent studies have described novel fusions involving the ROS1 and PDGFRβ genes in a subset of ALK-negative cases.” | 0.98 | hgnc_dict_v1 |
| gene | ALK | “ROS1 testing is often only considered after negative tests for EGFR mutation and ALK gene rearrangement, based on the assumption that these oncogenic driver events tend to be exclusive.” | 0.98 | hgnc_dict_v1 |
| gene | ALK | “CONTEXT: -The National Cancer Care Network and the combined College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology guidelines indicate that all lung adenocarcinomas (ADCs) should be tested for epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements.” | 0.98 | hgnc_dict_v1 |
| gene | ALK | “Activating alterations in several potential driver oncogenic genes have been identified, including EGFR, ROS1 and ALK and understanding of their molecular mechanisms underlying development, progression, and survival of lung cancer has led to the design of personalized treatments that have produced superior clinical outcomes in tumours harbouring these mutations.” | 0.98 | hgnc_dict_v1 |
| gene | ALK | “ALK gene amplification is associated with poor prognosis in colorectal carcinoma.” | 0.98 | hgnc_dict_v1 |